Elio Gentilini Cacciola

Dr. Elio Gentilini Cacciola

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ALAlessandro Lazzaro
Alessandro Lazzaro
ECElio Gentilini Cacciola
Elio Gentilini Cacciola
CBCristian Borrazzo
Cristian Borrazzo
GIGiuseppe Pietro Innocenti
Giuseppe Pietro Innocenti
ECEugenio Nelson Cavallari
Eugenio Nelson Cavallari
Gabriella d'EttorreGabriella d'Ettorre
Gabriella d'Ettorre
Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single tablet regimen for the treatment of people living with HIV-1 (PLWH). We aimed to assess efficacy, safety and tolerability of BIC/FTC/TAF among PLWH, with a specific focus on people older than 55 years. Thus, we recruited an observational retrospective real-life cohort including all PLWH who underwent a therapeutic switch to BIC/FTC/TAF, independently from the provenience treatment regimen. After 48 weeks of follow-up, 147 PLWH were included and 93 were older than 55 years. PLWH with HIV-RNA < 37 copies/mL increased from 140 to 146 (p < 0.033). Among the overall population, we observed an increase in CD4+ T cells count by 30.1% (p-value < 0.001), in CD8+ T cells count by 7.1% (p-value = 0.004) and in CD4+/CD8+ ratio by 21.5% (p-value < 0.001). Lipidic profile was characterized by decreasing total cholesterol/HDL ratio by 8% (p-value < 0.001) and LDL by 6.8% (p-value = 0.007). Total body weight increased by 1.8% (p-value = 0.014) and BMI by 4.2% (p-value < 0.001), even remaining within the healthy range. Hepatic and renal profile were not altered by the switch, nor were adverse events and/or discontinuations events detected. In conclusion, BIC/FTC/TAF is effective, safe and well tolerated in real life and among PLWH older than 55.

15 June 1991 in Blood
Verified
Journal Article
Open access
PDF file
ECElio Gentilini Cacciola
Elio Gentilini Cacciola
RGR Giustolisi
R Giustolisi
PGP Guglielmo
P Guglielmo
FRFrancesco Di Raimondo
Francesco Di Raimondo
RCRd Calogero
Rd Calogero
We read with interest the recently published article by R.T. Silver' regarding the use of recombinant interferon a (r-IFNa) in the management of polycythemia vera (PV). We report here our data' and comments regarding 11 consecutive PV patients treated with r-IFNa between November 1988 and March 1990. We think that our experience could be useful in providing additional insights into Silver's data. Our patients, diagnosed according to PV Study Group criteria, were 6 men and 5 women, ranged 16 to 79 years (mean, 57 years), all previously managed by either phlebotomy (6 patients) or hydroxyurea (5 patients). r-IFNa was administered at 3 X lo6 U/min daily continually for 6 months and at 3 x 106 U/i.m.

24 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Alessandro RussoAlessandro Russo
Alessandro Russo
EBErica Binetti
Erica Binetti
CBCristian Borrazzo
Cristian Borrazzo
ECElio Gentilini Cacciola
Elio Gentilini Cacciola
LBLuigi Battistini
Luigi Battistini
Gabriella d'EttorreGabriella d'Ettorre
Gabriella d'Ettorre
Objectives: Remdesivir is currently approved for the treatment of COVID-19. The recommendation for using remdesivir in patients with COVID-19 was based on the in vitro and in vivo activity of this drug against SARS-CoV-2. Methods: This was a prospective observational study conducted on a population of patients hospitalized for COVID-19. The primary endpoint of this study was the impact of remdesivir-containing therapy on 30-day mortality; the secondary endpoint was the impact of remdesivir-containing therapy on the need for high-flow oxygen therapy (HFNC), non-invasive ventilation (NIV), or mechanical ventilation. The data were analyzed after propensity score matching. Results: A total of 407 patients with SARS-CoV-2 pneumonia were consecutively enrolled. Out of these, 294 (72.2%) were treated with remdesivir and 113 (27.8%) were not. Overall, 61 patients (14.9%) were treated during hospitalization with HFNC, NIV, or mechanical ventilation, while 30-day mortality was observed in 21 patients (5.2%). Univariate analysis of patients treated with remdesivir or not showed no differences in 30-day mortality (4% vs. 6%, p = 0.411) in the two study groups. Cox regression analysis, after propensity score matching, showed that therapies, including remdesivir-containing therapy, were not statistically associated with 30-day survival or mortality. The Kaplan–Meier curves of 30-day survival in patients treated with remdesivir or not before (p = 0.24) and after (p = 0.88) propensity score matching showed no differences between the two study groups. Finally, patients treated with remdesivir or not showed the same need for HFNC/NIV or mechanical ventilation. Conclusions: This real-life experience of remdesivir use in hospitalized patients with COVID-19 was not associated with significant increases in rates of survival or reduced use of HFNC/NIV or mechanical ventilation compared with patients treated with other therapies not including remdesivir.

29 June 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Alessandro RussoAlessandro Russo
Alessandro Russo
CDChiara Davoli
Chiara Davoli
CBCristian Borrazzo
Cristian Borrazzo
VOVincenzo Olivadese
Vincenzo Olivadese
Giancarlo CeccarelliGiancarlo Ceccarelli
Giancarlo Ceccarelli
ETEnrico Maria Trecarichi
Enrico Maria Trecarichi
The hyperinflammatory phase represents the main cause for the clinical worsening of acute respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to the hypothesis that steroid therapy could be a mainstream treatment in COVID-19 patients. This is an observational study including all consecutive patients admitted to two Italian University Hospitals for COVID-19 from March 2020 to December 2021. The aim of this study was to describe clinical characteristics and outcome parameters of hospitalized COVID-19 patients treated with dexamethasone 6 mg once daily (standard-dose group) or methylprednisolone 40 mg twice daily (high-dose group). The primary outcome was the impact of these different steroid treatments on 30-day mortality. During the study period, 990 patients were evaluated: 695 (70.2%) receiving standard dosage of dexamethasone and 295 (29.8%) receiving a high dose of methylprednisolone. Cox regression analysis showed that chronic obstructive pulmonary disease (HR 1.98, CI95% 1.34–9.81, p = 0.002), chronic kidney disease (HR 5.21, CI95% 1.48–22.23, p = 0.001), oncologic disease (HR 2.81, CI95% 1.45–19.8, p = 0.005) and high-flow nasal cannula, continuous positive airway pressure or non-invasive ventilation oxygen therapy (HR 61.1, CI95% 5.12–511.1, p < 0.001) were independently associated with 30-day mortality; conversely, high-dose steroid therapy was associated with survival (HR 0.42, CI95% 0.38–0.86, p = 0.002) at 30 days. Kaplan–Meier curves for 30-day survival displayed a statistically significant better survival rate in patients treated with high-dose steroid therapy (p = 0.018). The results of this study highlighted that the use of high-dose methylprednisolone, compared to dexamethasone 6 mg once daily, in hospitalized patients with COVID-19 may be associated with a significant reduction in mortality.

29 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Alessandro RussoAlessandro Russo
Alessandro Russo
ECElio Gentilini Cacciola
Elio Gentilini Cacciola
CBCristian Borrazzo
Cristian Borrazzo
VFValeria Filippi
Valeria Filippi
TBTommaso Bucci
Tommaso Bucci
Gabriella d'EttorreGabriella d'Ettorre
Gabriella d'Ettorre
Objectives: COVID-19 may show no peculiar signs and symptoms that may differentiate it from other infective or non-infective etiologies; thus, early recognition and prompt management are crucial to improve survival. The aim of this study was to describe clinical, laboratory, and radiological characteristics and outcomes of hospitalized COVID-19 patients compared to those with other infective or non-infective etiologies. Methods: We performed a prospective study from March 2020 to February 2021. All patients hospitalized for suspected or confirmed COVID-19 were prospectively recruited. All patients were evaluated according to a predefined protocol for diagnosis of suspected SARS-CoV-2 infection. The primary endpoint was evaluation of clinical, laboratory, and radiological characteristics associated or not with COVID-19 etiology at time of hospitalization in an emergency department. Results: A total of 1036 patients were included in the study: 717 (69%) patients with confirmed COVID-19 and 319 (31%) without COVID-19, hospitalized for other causes. The main causes of hospitalization among non-COVID-19 patients were acute heart failure (44%) and bacterial pneumonia (45.8%). Overall, 30-day mortality was 9% among the COVID-19 group and 35% in the non-COVID-19 group. Multivariate analysis showed variables (fever > 3 days, dry cough, acute dyspnea, lymphocytes < 1000 × 103/µL, and ferritin > 250 ng/mL) independently associated with COVID-19 etiology. A decision tree was elaborated to early detect COVID-19 patients in the emergency department. Finally, Kaplan–Meier curves on 30-day survival in COVID-19 patients during the first wave (March–May 2020, n = 289 patients) and the second wave (October–February 2021, n = 428 patients) showed differences between the two study periods (p = 0.021). Conclusions: Patients with confirmed diagnosis of COVID-19 may show peculiar characteristics at time of hospitalization that could help physicians to distinguish from other infective or non-infective etiologies. Finally, a different 30-day mortality rate was observed during different periods of the pandemic.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
GNGiuseppe Noce
Giuseppe Noce
ECElio Gentilini Cacciola
Elio Gentilini Cacciola
PVPaolo Vassalini
Paolo Vassalini
DJDharmendra Jakhar
Dharmendra Jakhar
FTFederico Tucci
Federico Tucci
Claudio BabiloniClaudio Babiloni
Claudio Babiloni
Background: Previous evidence showed that persons experiencing post‐COVID‐19 with “brain fog” were characterized by abnormal resting‐state electroencephalographic (rsEEG) rhythms reflecting vigilance dysfunctions. In the present exploratory study, we tested the hypothesis that in post‐COVID persons with normal cognitive status, abnormalities in those rhythms (and vigilance function) may be related to fatigue.Method: We enrolled post‐COVID participants about one year after their infection, which claimed “brain fog.” They underwent clinical/neuropsychological assessment and 61‐channel‐EEG recordings. Matched controls (never COVID‐19 affected) were included. Using eLORETA freeware, regional neural current densities were estimated in the rsEEG cortical sources at individual delta, theta, and alpha bands and at beta and gamma fixed bands. Clinical and instrumental data were evaluated in the long COVID‐19 patients as a function of fatigue symptoms over the controls.Result: The post‐COVID patients had no cognitive deficits at the group level. Those patients showed lower posterior rsEEG alpha source activities than the controls. Notably, this effect was more significant with the long COVID‐19 patients experiencing fatigue symptoms than those without (Fig. 1).Conclusion: In post‐COVID patients with normal cognition, abnormal rsEEG alpha source activation may indicate a significant relationship between vigilance dysfunction and fatigue.